Table 3.
Exon capture sequencing results of 15 patients treated on study.
| Age | Gender | BORR | BRAF | NRAS | PTEN | MEK1 | CDKN2a | Other |
|---|---|---|---|---|---|---|---|---|
| Low pAKT cohort | ||||||||
| 70 | M | -27% | V600E | Deleted | NF2 (R187K); RB1 (E79K); PIK3C2G (R1069Q); MITF amp | |||
| 71¶ | F | -55% | V600E/amp | Deleted | Deleted | MITF amp; PTCH1 (P1315L) | ||
| 73 | F | -27% | V600E | G132C | P124S | G101W | PTPRD (D1521A); KIT amp; GRIN2A (G751W) | |
| 75¶ | F | 3% | V600E | R80* | TP53 (P87S); NF1 (S2701F); EGFR (G796S); ARID1A (1334_1335 insQ); PTCH1 (P1315L) | |||
| 23 | M | 54% | V600E | K57N | Deleted | NOTCH2 (P6fs); EPHA6 (G277E); TET1 (A896V) | ||
| High pAKT cohort | ||||||||
| 54 | M | 13% | Q61K | P124S | H83N | EPHA6 (P1055L); NOTCH2 (P2335S); GIN2A (E1202K); GNAQ (TD6S)/deleted | ||
| 69 ¶ | M | 68% | V600K | ERB4 (Q707E/N706fs); CDKN2C amp; MITF amp; ARID1A (Q1363*); PTPRD (E905K); PTCH1 (Q628*); GRIN2A (P985L); MYC amp; DAXX amp | ||||
| 53 | F | 13% | V600E | Insufficient tumor available | ||||
| 59 | M | 11% | V600E | Insufficient tumor available | ||||
| 75 | M | 24% | V600E | Insufficient tumor available | ||||
| 63 | M | 0% | V600E | Insufficient tumor available | ||||
| 63 | M | 13% | V600E | Insufficient tumor available | ||||
| 79 | M | -10% | V600K | Insufficient tumor available | ||||
| 69 | M | 8% | V600E | Insufficient tumor available | ||||
| 53 | M | 14% | V600E | Insufficient tumor available | ||||
Abbreviations: BORR, best overall response as expressed by change in tumor size; amp, amplified.Blank cells indicate wild-type genotypes.
Blank cells indicate wild-type genotypes.
*
Germline DNA was not available for these patients.